NASDAQ:ANL 延时15分钟

成交量

Yang Lu: Yang Lu is the founder of Adlai Nortye Ltd., where he currently serves as the Chairman & Chief Executive Officer. He founded the company in 2018. Mr. Lu previously worked as the Managing Director at Sinopep-Allsino Bio Pharmaceutical Co., Ltd. from 2004 to 2006. Mr. Lu holds an MBA from China Europe International Business School, which he obtained in 2012. He also completed his undergraduate studies at Xiamen University in 2002.

Ming Lun Tse: Ming Lun Tse currently works at Tian Ge Interactive Holdings Ltd., as Independent Non-Executive Director from 2022, Adlai Nortye Ltd., as Independent Non-Executive Director from 2021, and Association of Chartered Certified Accountants (Hong Kong), as Member from 2005. Mr. Tse also formerly worked at Next Horizon Co. Ltd., as Senior Manager-Corporate Planning & Development from 2007 to 2009. Mr. Tse received his undergraduate degree in 2002 from The University of Hong Kong.

Lars E. Birgerson: Lars E. Birgerson is currently the President & Chief Executive Officer at Adlai Nortye USA, Inc., the Director at Trialbee AB, the Director at Adlai Nortye Ltd., and the President at Hangzhou Adlai Nortye Biopharma Co. Ltd. Previously, he held positions as the Vice President-Medical Affairs at Genentech, Inc., the Vice President, Head-Global & US Medical Affairs at Roche Pharma (Schweiz) AG, and the Chief Medical Officer at Adlai Nortye Ltd. He obtained his doctorate degrees from the University of Uppsala in 1990 and 1977.

Shao Rong Liu: Shao Rong Liu is an Independent Director at Adlai Nortye Ltd. since 2023. Previously, he served as an Independent Director at CoCreation Grass Co., Ltd. from 2018 to 2024. Mr. Liu holds an MBA from China Europe International Business School, conferred in 2012.

Roger A. Sawhney: Roger A. Sawhney currently works at SIRPant Immunotherapeutics, Inc., as Director from 2024, Arbutus Biopharma Corp., as Director from 2025, Adlai Nortye Ltd., as Director from 2024, and Actuate Therapeutics, Inc., as Independent Director from 2024. Dr. Sawhney also formerly worked at Alimera Sciences, Inc., as Director in 2023, The Boston Consulting Group, Inc., as Managing Director & Partner from 1996 to 2009, KKR Group Co., Inc., as Director from 2018 to 2020, Arcellx, Inc., as Independent Director, New York Institute of Technology, as Director, ContextMedia Health LLC, as SVP-Corporate Strategy & Business Development from 2017 to 2018, Novartis AG, as Senior VP & Head-Global Corporate Strategy from 2009 to 2012, Stratus Therapeutics, Inc., as Chief Financial Officer from 2022 to 2023, Bain & Co., Inc., as Partner from 2012 to 2017, Omega Therapeutics, Inc., as Chief Business Officer in 2022, and LB Pharmaceuticals, Inc., as Chief Financial Officer. Dr. Sawhney received his undergraduate degree from Stanford University and doctorate degree from Harvard Medical School.

阿诺医药